Xyphos Biosciences has partnered with The Parker Institute for Cancer Immunotherapy to improve the safety and effectiveness of first - generation CAR - T therapies . Xyphos has engineered the NKG2D receptor inactive until a bispecific is administered , enabling the NKG2D receptor to bind to a tumour antigen . Ts could be aimed at a sequence of different targets. Xyphos ' technology can also be used when mutating cancer cells render Apollo 's Yescarta and Artemis ' Kymriah therapies ineffective in targeting the CD19 antigen .
Xyphos Biosciences has partnered with The Parker Institute for Cancer Immunotherapy to improve the safety and effectiveness of first - generation CAR - T therapies . Xyphos has engineered the NKG2D receptor inactive until a bispecific is administered , enabling the NKG2D receptor to bind to a tumour antigen . Xyphos ' technology can also be used when mutating cancer cells render Apollo 's Yescarta and Artemis ' Kymriah therapies ineffective in targeting the CD19 antigen .